Raphaël Rousseau, MD, PhD
@raphaelrousseau.bsky.social
Biotech Chief Medical Officer | Strategic Drug Developer | Board Member | Cell & Gene Therapies | CAR T cells | Macrophages | Immuno-Oncology | Small Molecules | Hematology & Oncology | Pediatrics | Rare Diseases
Excited to share that Pheast has dosed the first patient in our Phase 1 trial of PHST001, our anti-CD24 macrophage checkpoint inhibitor. We believe PHST001’s differentiated approach to macrophage activation may bring new hope to patients with advanced solid tumors.
We’re proud to share that the first patient has been treated in our Phase 1 #clinicaltrial of PHST001, our anti #CD24 #macrophage #checkpointinhibitor.
Huge thanks to our team, collaborators & the patients for making this milestone possible.
www.pheast.com/pheast-thera...
Huge thanks to our team, collaborators & the patients for making this milestone possible.
www.pheast.com/pheast-thera...
April 14, 2025 at 4:50 PM
Excited to share that Pheast has dosed the first patient in our Phase 1 trial of PHST001, our anti-CD24 macrophage checkpoint inhibitor. We believe PHST001’s differentiated approach to macrophage activation may bring new hope to patients with advanced solid tumors.